Term
|
Definition
Hypothyroidism
Levothyroxine is a T4 Analog |
|
|
Term
|
Definition
Used to treat myxedema coma
Liothyrionine is a T3 analog |
|
|
Term
|
Definition
| Alternate substrate for thyroperoxidase, inhibition of thyroxin synthesis, inhibition of coupling to form thyroglobulin, inhibition of T4->T3, Disease: Hyperthyroidism, especially during pregnancy doesn't cross placenta or into breast milk |
|
|
Term
|
Definition
| Alternate substrate for throperoxidase, inhibiton of thyroxin synthesis, inhibiton of coupling to form thyroglobulin Disease Use: Hyperthyroidism, SE: crosses placenta and into breast milk |
|
|
Term
|
Definition
| Concentration in and destruction of thyroid tissue Disease: hyperthyroidism |
|
|
Term
|
Definition
| Inhibition of thyroid hormone synthesis and release, reduction of thyroid gland vascularity, reduction of thyroid cell proliferation. Disease: hyperthyroidism preparative to thyroidectomy |
|
|
Term
|
Definition
| Disease: type 1 and type 2 diabetes |
|
|
Term
|
Definition
| Long-acting Katp channel blocker, causes influx of Ca via voltage depedent Ca channel in Beta Cells increases insulin secretion Disease: Type 2 diabetes |
|
|
Term
|
Definition
| Long-acting Katp channel blocker, increases insulin secretion Disease: Type 2 diabetes |
|
|
Term
|
Definition
| GLP-1 agonist; potentiation of insulin secretion, inhibition of glucagon secretion Disease: Type 2 diabetes |
|
|
Term
|
Definition
| DPP-IV inhibitor; slows breakdown of GLP-1 and GIP Disease: Type 2 diabetes |
|
|
Term
|
Definition
i) Decreases hepatic glucose production
ii) Potentiates insulin action in peripheral tissues by - increasing cell surface insulin receptors - Increasing Glut 4 glucose transporters - Increasing glucose uptake iii) Metformin activates 5’ AMP kinase, which increases fatty acid oxidation, reducing tissue lipids and alleviating insulin resistance
i) Usually modest weight loss
ii) No hypoglycemia
iii) Decreases plasma (VLDL) and triglycerides
iv) Does not change or slightly decreases plasma insulin levels i) Usually modest weight loss ii) No hypoglycemia iii) Decreases plasma very low density lipoprotein (VLDL) and triglycerides iv) Does not change or slightly decreases plasma insulin levels Side Effects: The major side effects are gastrointestinal discomfort and diarrhea. The most serious potential toxic side effect is development of lactic acidosis. rare occur in patients predisposed to develop lactic acidosis, Disease: Type 2 diabetes Class: biguanides |
|
|
Term
|
Definition
| Activation of peroxisome proliferator-activated receptor (PPAR), increase in insulin-stimulated rate of glucose utilization, reduced lipolysis and increased fat storage, reduced cytokine production, increased adiponectin production Disease: Type 2 diabetes |
|
|
Term
|
Definition
| Activation of peroxisome proliferator-activated receptor (PPAR), increase in insulin-stimulated rate of glucose utilization, reduced lipolysis and increased fat storage, reduced cytokine production, increased adiponectin production Disease: Type 2 diabetes |
|
|
